Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.53 |
| ▸ | SLC18A3 | Q16572 | 5/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711267 | 0.83 | SLC18A3 (0.50) | SLC18A3SIGMAR1AKR1C3AKR1C1DRD2 | |
| SCHEMBL23124105 | 0.83 | SLC18A3 (0.53) | SLC18A3SIGMAR1AKR1C3AKR1C1DRD2 | |
| SCHEMBL3028543 | 0.82 | CHRM2 (0.59) | SLC18A3SIGMAR1 | |
| SCHEMBL16358521 | 0.82 | CHRM2 (0.59) | SLC18A3SIGMAR1 | |
| SCHEMBL14081578 | 0.77 | CHRM1 (0.56) | SLC18A3SIGMAR1 | |
| SCHEMBL13328860 | 0.75 | RIPK1 (0.58) | RIPK1 | |
| SCHEMBL21467223 | 0.75 | OPRM1 (0.46) | RIPK1OPRM1OPRD1 | |
| SCHEMBL18701767 | 0.75 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL18701866 | 0.74 | RIPK1 (0.45) | RIPK1 | |
| SCHEMBL18702251 | 0.74 | SPR (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | RIPK1 2586/4885SLC18A3 1255/4885SIGMAR1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.